首页> 美国卫生研究院文献>Molecular Therapy. Methods Clinical Development >Total body irradiation must be delivered at high dose for efficient engraftment and tolerance in a rhesus stem cell gene therapy model
【2h】

Total body irradiation must be delivered at high dose for efficient engraftment and tolerance in a rhesus stem cell gene therapy model

机译:在恒河猴干细胞基因治疗模型中必须高剂量全身照射才能有效植入并耐受

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Reduced intensity conditioning (RIC) is desirable for hematopoietic stem cell (HSC) gene therapy applications. However, low gene marking was previously observed in gene therapy trials, suggesting that RIC might be insufficient for (i) opening niches for efficient engraftment and/or (ii) inducing immunological tolerance for transgene-encoded proteins. Therefore, we evaluated both engraftment and tolerance for gene-modified cells using our rhesus HSC gene therapy model following RIC. We investigated a dose de-escalation of total body irradiation (TBI) from our standard dose of 10Gy (10, 8, 6, and 4Gy), in which rhesus CD34+ cells were transduced with a VSVG-pseudotyped chimeric HIV-1 vector encoding enhanced green fluorescent protein (GFP) (or enhanced yellow fluorescent protein (YFP)). At ~6 months after transplantation, higher-dose TBI resulted in higher gene marking with logarithmic regression in peripheral blood cells. We then evaluated immunological tolerance for gene-modified cells, and found that lower-dose TBI allowed vigorous anti-GFP antibody production with logarithmic regression, while no significant anti-VSVG antibody formation was observed among all TBI groups. These data suggest that higher-dose TBI improves both engraftment and immunological tolerance for gene-modified cells. Additional immunosuppression might be required in RIC to induce tolerance for transgene products. Our findings should be valuable for developing conditioning regimens for HSC gene therapy applications.
机译:降低强度的调节(RIC)对于造血干细胞(HSC)基因治疗应用是理想的。但是,以前在基因治疗试验中观察到低基因标记,这表明RIC可能不足以(i)为有效植入而打开壁ni和/或(ii)诱导转基因编码蛋白的免疫耐受。因此,我们在RIC后使用我们的恒河猴HSC基因治疗模型评估了基因修饰细胞的植入和耐受性。我们研究了从我们的标准剂量10Gy(10、8、6和4Gy)降低全身辐射(TBI)的剂量,其中用VSVG-转导了恒河猴CD34 + 细胞编码增强型绿色荧光蛋白(GFP)(或增强型黄色荧光蛋白(YFP))的假型嵌合HIV-1载体。移植后约6个月,大剂量TBI导致外周血细胞中的基因标记较高,对数退化。然后,我们评估了基因修饰细胞的免疫耐受性,发现低剂量的TBI可以使抗GFP抗体的产生呈对数回归,而在所有TBI组中均未观察到明显的抗VSVG抗体形成。这些数据表明,高剂量的TBI可以改善基因修饰细胞的植入和免疫耐受性。 RIC可能需要额外的免疫抑制以诱导对转基因产物的耐受性。我们的发现对于开发用于HSC基因治疗应用的调节方案应该是有价值的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号